WALSH MCDERMOTT; CARL MUSCHENHEIM, F.A.C.P.; SUSAN J. HADLEY; PAUL A. BUNN; ROSEMARY V. GORMAN
Shortly after the first report on streptomycin by Waksman and his associates,1 Feldman and Hinshaw observed that the drug exerted a pronounced effect upon the course of tuberculous infections in guinea pigs.2 On the basis of these findings, a clinical investigation was started, and in September 1945 Hinshaw and Feldman reported that streptomycin exerted a suppressive effect upon the course of various forms of tuberculous infections in humans.3 Although the therapeutic claims of these investigators were notably restrained in this and their subsequent reports,4, 5 it was apparent that the alterations in the course of tuberculous infections observed by
Learn more about subscription options.
Register Now for a free account.
MCDERMOTT W, MUSCHENHEIM C, HADLEY SJ, BUNN PA, GORMAN RV. STREPTOMYCIN IN THE TREATMENT OF TUBERCULOSIS IN HUMANS: I. MENINGITIS AND GENERALIZED HEMATOGENOUS TUBERCULOSIS(I. MENINGITIS AND GENERALIZED HEMATOGENOUS TUBERCULOSIS*). Ann Intern Med. 1947;27:769–822. doi: 10.7326/0003-4819-27-5-769
Download citation file:
Published: Ann Intern Med. 1947;27(5):769-822.
CNS Infections, Infectious Disease, Mycobacterial Infections, Neurology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only